Adverse Drug ReactionNCT02094638
Post-Marketing Surveillance of the Tanreqing Injection: a Real World Study
An observational study of Adverse Drug Reaction and Drug Allergy, run by Suodi ZHAI at 90 sites in China.
Trial summary
Tanreqing Injection is widely used in respiratory disease with Chinese medicine syndrome of retention of phlegm and heat in Fei. This study record clinical use of Tanreqing Injection in the real world, observe the adverse drug reactions/ adverse drug events during treatment, and figure out why Tanreqing induced severe… Read more about this study
- Who is it for?
- Ages 24 months and older
- Conditions the study is for
- Adverse Drug Reaction, Drug Allergy
- Type of treatment
- Injection or infusion
- How many people
- 30,400 participants
- Where
- 90 sitesChina
- Study dates
- Jan 2014to Aug 2015
- How long will I take part?
- 7 Days
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 24 months and older
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Study population: Patients who use the Tanreqing Injection in selected hospitals in China (including the inpatient and the outpatient(only in some hospitals which can get the information)).
Who may be able to join
- Patients who use the Tanreqing Injection in selected hospitals in China, including inpatient and outpatient.
- Outpatients will be only in some hospitals which can get the patients' complete information.
Who cannot join
- Patients who are less than 24 months.
Trial locations and contacts
90 sites in 1 country.
90 sites in 1 country
China90 sites
People's Hospital of Rongcheng
Baoding, Hebei, 071700
The Third Affiliated Hospital of Inner Mongolia Medical College
Baotou, Inner Mongolia, 014010
The Fengtai district Hospital of Integrated TCM & WM
Beijing, Beijing Municipality, 100072
Beijing Geriatric Hospital
Beijing, Beijing Municipality, 100095
The 263rd Hospital of Chinese People's Liberation Army
Beijing, Beijing Municipality, 101100
Beijing Luhe Hospital, Capital Medical University
Beijing, Beijing Municipality, 101149
Peking university third hospital
Beijing, 100191
Bijie First Municipal People's Hospital
Bijie, Guizhou, 551700
People's Hospital of Cangzhou
Cangzhou, Hebei, 061000
The First Hospital of Jilin University
Changchun, Jilin, 130021
The Second Hospital of Jilin University
Changchun, Jilin, 130041
The Fourth Hospital of Changsha
Changsha, Hunan, 410006
the Second Xiangya Hospital of Central South University
Changsha, Hunan, 410011
The Third People's Hospital of Chengdu
Chengdu, Sichuan, 610031
West China Hospital, Sichuan University
Chengdu, Sichuan, 610041
Sichuan Provincial People's Hospital
Chengdu, Sichuan, 610072
ShuangLiu Hospital of Traditional Chinese Medical
Chengdu, Sichuan, 610200
The Second Affiliated Hospital of Chongqing Medical University
Chongqing, Chongqing Municipality, 400010
The Third People's Hospital of Chongqing
Chongqing, Chongqing Municipality, 400014
Chongqing Traditional Chinese Medicine Hospital
Chongqing, Chongqing Municipality, 400021
Chongqing Jiulongpo First People's Hospital
Chongqing, Chongqing Municipality, 400050
Chongqing Three Gorges Central Hospital
Chongqing, Chongqing Municipality, 404000
Chongqing Kaixian County People's Hospital
Chongqing, Chongqing Municipality, 405400
Traditional Chinese Medical Hospital of Bai Autonomous Prefecture of Dali
Dali, Yunnan, 671099
Fifth Hospital of Datong
Datong, Shanxi, 037006
DuJiangyan Traditional Chinese Medicine Hospital
Dujiangyan, Sichuan, 611830
Fenyang Hospital of Shanxi Province
Fenyang, Shanxi, 032200
Guiyang Children's Hospital
Guiyang, Guizhou, 550003
Guiyang Pulmonary Hospital
Guiyang, Guizhou, 550003
Guizhou Cancer Hospital
Guiyang, Guizhou, 550003
The 44th Hospital of chinese People's Liberation Army
Guiyang, Guizhou, 550009
The Affiliated Hospital of Hainan medical College
Haikou, Hainan, 570102
First Hospital of Handan City
Handan, Hebei, 056002
Zhejiang Provincial Hospital of TCM
Hangzhou, Zhejiang, 310006
Anhui Provincial Children's Hospital
Hefei, Anhui, 230051
Hejian Municipal People's Hospital
Hejian, Hebei, 062450
The First Hospital Of Huhhot
Hohhot, Inner Mongolia, 010030
The fourth Hospital of Inner Mongolia
Hohhot, Inner Mongolia, 010080
The Third People's Hospital of Huizhou
Huizhou, Guangdong, 516002
Affiliated Hospital of Shandong University of Traditional Chinese Medicine
Jinan, Shandong, 250011
Shandong Cancer Hospital
Jinan, Shandong, 250117
The Second People's Hospital of Jinzhong
Jinzhong, Shanxi, 030800
First Affiliated Hospital of Kunming Medical University
Kunming, Yunnan, 650032
Second Affiliated Hospital of Kunming Medical University
Kunming, Yunnan, 650101
Gansu Provincial Hospital of Traditional Chinese Medicine
Lanzhou, Gansu, 730050
Lanzhou Petrochemical General Hospital
Lanzhou, Gansu, 730060
The Second Hospital of Nanchang
Nanchang, Jiangxi, 330003
Jiangxi Provincial People's Hospital
Nanchang, Jiangxi, 330006
Traditional Chinese Medical Hospital of Jiangxi Province
Nanchang, Jiangxi, 330006
The First Hospital of Nanchang
Nanchang, Jiangxi, 330008
People's Hospital of Nanbu County
Nanchong, Sichuan, 637300
Jiangning District Hospital of Traditional Chinese Medicine
Nanjing, Jiangsu, 211100
Ningbo First Hospital
Ningbo, Zhejiang, 315010
The 152nd Hospital of chinese People's Liberation Army
Pingdingshan, Henan, 467000
The First Hospital of Qinhuangdao
Qinhuangdao, Hebei, 066000
Shanghai Changzheng Hospital
Shanghai, Shanghai Municipality, 200003
Shanghai Ninth People's Hospital, Shanghai JiaoTong University School of Medicine
Shanghai, Shanghai Municipality, 200011
Shanghai First People's Hospital Branch
Shanghai, Shanghai Municipality, 200081
Wu Song Central Hospital of Shanghai
Shanghai, Shanghai Municipality, 200940
Shanghai Minhang District Central Hospital
Shanghai, Shanghai Municipality, 201199
Shenyang 242 Hospital
Shenyang, Liaoning, 110034
The Third People's Hospital of Shenzhen
Shenzhen, Guangdong, 518112
the Second Hospital of Hebei Medical University
Shijiazhuang, Hebei, 050000
Bethune International Peace Hospital of the Chinese PLA
Shijiazhuang, Hebei, 050082
Hebei Zhaoxian People's Hospital
Shijiazhuang, Hebei, 051530
The Center Hospital of Shuozhou
Shuozhou, Shanxi, 036002
Maternal and Child Health Care Hospital of Taiyuan
Taiyuan, Shanxi, 030012
Shanxi Maternity and Children Health Hospital
Taiyuan, Shanxi, 030013
The 254th Hospital of chinese People's Liberation Army
Tianjin, Tianjin Municipality, 300142
The 464th Hospital of chinese People's Liberation Army
Tianjin, Tianjin Municipality, 300381
People's Hospital of Xinjiang Uigur Autonomous Region
Ürümqi, Xinjiang, 830011
Wenzhou Central Hospital
Wenzhou, Zhejiang, 325000
The Second Affiliated Hospital of Wenzhou Medical College
Wenzhou, Zhejiang, 325027
Wenzhou Yueqing People's Hospital
Wenzhou, Zhejiang, 325699
Hubei Xinhua Hospital
Wuhan, Hubei, 430015
Hubei Zhongshan Hospital Affiliated to Wuhan University
Wuhan, Hubei, 430033
Hubei Cancer Hospital
Wuhan, Hubei, 430079
The Second Hospital of Wulanchabu City
Wulanchabu, Inner Mongolia, 012000
Qinghai Women and Childhood Hospital
Xining, Qinghai, 810007
Xinle Municipal Hospital of Hebei
Xinle, Hebei, 050700
Xintai People's Hospital
Xintai, Shandong, 271200
The First People's Hospital of Yangzhou City
Yangzhou, Jiangsu, 225002
Yantai Municipal Laiyang Central Hospital
Yantai, Shandong, 265200
The First People's Hospital of Yinchuan
Yinchuan, Ningxia, 750001
General Hospital of Ningxia Medical University
Yinchuan, Ningxia, 750004
Chinese Traditional Medicine Hospital of Ningxia Autonomous Region
Yinchuan, Ningxia, 750021
Henan Province Hospital of TCM
Zhengzhou, Henan, 450002
The First Affiliated Hospital of Zhengzhou University
Zhengzhou, Henan, 450052
Zhongshan Municipal People's Hospital
Zhongshan, Guangdong, 528403
Affiliated Hospital of Zunyi Medical College
Zunyi, Guizhou, 563000
About this study
Tanreqing Injection is widely used in respiratory disease with Chinese medicine syndrome of retention of phlegm and heat in Fei. This study record clinical use of Tanreqing Injection in the real world, observe the adverse drug reactions/ adverse drug events during treatment, and figure out why Tanreqing induced severe allergic reaction happens.
Read the detailed description
As a compound traditional Chinese medicine, Tanreqing Injection was approved by China Food and Drug Administration(CFDA) in 2003, and widely used respiratory disease, such as biofilm related upper respiratory infections, pneumonia and bronchitis. During its 11 years marketing in China, there was hardly any serious adverse drug reactions except for a few cases reported as severe allergic reaction. In this study, clinical pharmacists in selected hospitals will not only record the clinical use and the adverse drug reactions/ adverse drug events of this injection, but also try to figure out why drug-induced severe allergic reaction happens through a nested case-control study. This real world study for Tanreqing Injection with 30400 patients will be conducted from January.2014 to June.2016.
- Conditions
- Adverse Drug Reaction, Drug Allergy
- Keywords
- Traditional Chinese Medicine Injection
- Medical subject headings
- Drug-Related Side Effects and Adverse Reactions, Drug Hypersensitivity
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| Tanreqing | Inpatient using the Tanreqing Injection |
What is being measured
The primary outcome is the main question the study is designed to answer.
Incidence of adverse drug reaction of Tanreqing Injection
Measured: 30 months
Secondary outcomes (5)
Outcomes of the patients who experienced an adverse drug reaction of Tanreqing Injection
Outcomes including cure, improved, null, or death.
Measured: 30 months
Administration of Tanreqing Injection in real world
Measured: 30 months
Population characteristics of the adverse drug reaction of Tanreqing Injection
Measured: 30 months
Off-lable use of Tanreqing Injection
Measured: 30 months
Drug combination of Tanreqing Injection in real world
Measured: 30 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted24 Mar 2014 (estimated)
- Study startJan 2014
- Primary completionAug 2015
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Adverse Drug ReactionStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Enrolment
- 30,400 participants (estimated)
- Target duration
- 7 Days
Sponsor and investigators
- Lead sponsor
- Suodi ZHAI
- Sponsor type
- University, hospital or other
- Collaborators
- Shanghai Kaibao Pharmaceutical CO.,LTD., Peking University, Handan First Hospital, Bethune International Peace Hospital of the Chinese PLA, The 254th Hospital of chinese People's Liberation Army, The 464th Hospital of chinese People's Liberation Army, People's Hospital of Cangzhou, The First Hospital of Qinhuangdao, The 44th Hospital of chinese People's Liberation Army, First Affiliated Hospital of Kunming Medical University, The Second Affiliated Hospital of Kunming Medical University, Chongqing Three Gorges Central Hospital, Sichuan Provincial People's Hospital, ShuangLiu Hospital of Traditional Chinese Medical, People's Hospital of Nanbu County, DuJiangyan Traditional Chinese Medicine Hospital, West China Hospital, Chongqing Traditional Chinese Medicine Hospital, The Third People's Hospital of Chongqing, Changsha Fourth Hospital, Hubei Xinhua Hospital, Wenzhou Central Hospital, Affiliated Yueqing Hospital of Wenzhou Medical University, The First Affiliated Hospital of Nanchang University, Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University, Shanghai Minhang District Central Hospital, Shanghai First People's Hospital Branch, Zhejiang Provincial Hospital of TCM, The Affiliated Hospital of Hainan medical College, Guiyang Children's Hospital, Traditional Chinese Medical Hospital of Jiangxi Province, Jiangxi Provincial People's Hopital, Hubei Cancer Hospital, Jiangning District Hospital of Traditional Chinese Medicine, Shenzhen Third People's Hospital, Ningbo No. 1 Hospital, Second Hospital of Jilin University, The First Hospital of Jilin University, Yangzhou No.1 People's Hospital, Traditional Chinese Medical Hospital of Bai Autonomous Prefecture of Dali, Bijie First Municipal People's Hospital, Guiyang Pulmonary Hospital, The 263rd Hospital of Chinese People's Liberation Army, Chongqing Kaixian County People's Hospital, The Second Affiliated Hospital of Chongqing Medical University, Chongqing Jiulongpo First People's Hospital, People's Hospital of Xinjiang Uygur Autonomous Region, Shenyang 242 Hospital, Second Affiliated Hospital of Guangzhou Medical University, Cancer Hospital of Guizhou Province, Wu Song Central Hospital of Shanghai, Gansu Provincial Hospital, Lanzhou Petrochemical General Hospital, Traditional Chinese Medicine Hospital of the Ningxia Hui Autonomous Region, General Hospital of Ningxia Medical University, The First People's Hospital of Yinchuan, Yantai Municipal Laiyang Central Hospital, Shandong Cancer Hospital and Institute, Shandong University of Traditional Chinese Medicine, Zunyi Medical College, 152nd Hospital of Chinese People's Liberation Army, The Second Affiliated Hospital of Henan University of Traditional Chinese Medicine, The First Affiliated Hospital of Zhengzhou University, Central South University, The Second Hospital of Nanchang, The Second Hospital of Wulanchabu City, Qinghai Women and Childhood Hospital, The Third People's Hospital of Chengdu, The Center Hospital of Shuozhou, Yunnan Provinical Hospital of Traditional Chinese Medicine, Beijing Geriatric Hospital, Hubei Zhongshan Hospital Affiliated to Wuhan University, Anhui Provincial Children's Hospital, The Third Affiliated Hospital of Inner Mongolia Medical College, The fourth Hospital of Inner Mongolia, Zhongshan People's Hospital, Guangdong, China, Fenyang Hospital of Shanxi Province, The First Hospital Of Huhhot, Taiyuan Xinghualing Maternity & Child Health Care Center, The Fifth People's Hospital of Datong, Shanxi Provincial Maternity and Children's Hospital, The Second People's Hospital of Jinzhong, The Second Hospital of Hebei Medical University, People's Hospital of Rongcheng, Hebei Zhaoxian People's Hospital, Hejian Municipal People's Hospital, Xinle Municipal Hospital of Hebei, Capital Medical University, Fengtai district Hospital of Chinese and Western medicine, Beijing, Shanghai Changzheng Hospital, Xintai People's Hospital
- Responsible party
- Sponsor-investigator, Suodi ZHAI, Peking University Third Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02094638
- Sponsor's protocol ID
- PekingUTH-Pharmacy-003
- Status last verified
- Feb 2016
- First submitted
- 20 Mar 2014
- Last updated
- 19 Feb 2016
- Results posted
- No
- Data monitoring committee
- Yes
Study at a glance
From the registry record, last updated by the sponsor on 19 Feb 2016. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Post-Marketing Surveillance of the Tanreqing Injection: a Real World Study
- ClinicalTrials.gov ID
- NCT02094638
- Acronym / sponsor ID
- PekingUTH-Pharmacy-003
- Conditions
- Adverse Drug Reaction, Drug Allergy
- Keywords
- Traditional Chinese Medicine Injection
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 30,400 participants (estimated)
- Lead sponsor
- Suodi ZHAIUniversity, hospital or other
- Collaborators
- Shanghai Kaibao Pharmaceutical CO.,LTD., Peking University, Handan First Hospital, Bethune International Peace Hospital of the Chinese PLA, The 254th Hospital of chinese People's Liberation Army, The 464th Hospital of chinese People's Liberation Army, People's Hospital of Cangzhou, The First Hospital of Qinhuangdao, The 44th Hospital of chinese People's Liberation Army, First Affiliated Hospital of Kunming Medical University, The Second Affiliated Hospital of Kunming Medical University, Chongqing Three Gorges Central Hospital, Sichuan Provincial People's Hospital, ShuangLiu Hospital of Traditional Chinese Medical, People's Hospital of Nanbu County, DuJiangyan Traditional Chinese Medicine Hospital, West China Hospital, Chongqing Traditional Chinese Medicine Hospital, The Third People's Hospital of Chongqing, Changsha Fourth Hospital, Hubei Xinhua Hospital, Wenzhou Central Hospital, Affiliated Yueqing Hospital of Wenzhou Medical University, The First Affiliated Hospital of Nanchang University, Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University, Shanghai Minhang District Central Hospital, Shanghai First People's Hospital Branch, Zhejiang Provincial Hospital of TCM, The Affiliated Hospital of Hainan medical College, Guiyang Children's Hospital, Traditional Chinese Medical Hospital of Jiangxi Province, Jiangxi Provincial People's Hopital, Hubei Cancer Hospital, Jiangning District Hospital of Traditional Chinese Medicine, Shenzhen Third People's Hospital, Ningbo No. 1 Hospital, Second Hospital of Jilin University, The First Hospital of Jilin University, Yangzhou No.1 People's Hospital, Traditional Chinese Medical Hospital of Bai Autonomous Prefecture of Dali, Bijie First Municipal People's Hospital, Guiyang Pulmonary Hospital, The 263rd Hospital of Chinese People's Liberation Army, Chongqing Kaixian County People's Hospital, The Second Affiliated Hospital of Chongqing Medical University, Chongqing Jiulongpo First People's Hospital, People's Hospital of Xinjiang Uygur Autonomous Region, Shenyang 242 Hospital, Second Affiliated Hospital of Guangzhou Medical University, Cancer Hospital of Guizhou Province, Wu Song Central Hospital of Shanghai, Gansu Provincial Hospital, Lanzhou Petrochemical General Hospital, Traditional Chinese Medicine Hospital of the Ningxia Hui Autonomous Region, General Hospital of Ningxia Medical University, The First People's Hospital of Yinchuan, Yantai Municipal Laiyang Central Hospital, Shandong Cancer Hospital and Institute, Shandong University of Traditional Chinese Medicine, Zunyi Medical College, 152nd Hospital of Chinese People's Liberation Army, The Second Affiliated Hospital of Henan University of Traditional Chinese Medicine, The First Affiliated Hospital of Zhengzhou University, Central South University, The Second Hospital of Nanchang, The Second Hospital of Wulanchabu City, Qinghai Women and Childhood Hospital, The Third People's Hospital of Chengdu, The Center Hospital of Shuozhou, Yunnan Provinical Hospital of Traditional Chinese Medicine, Beijing Geriatric Hospital, Hubei Zhongshan Hospital Affiliated to Wuhan University, Anhui Provincial Children's Hospital, The Third Affiliated Hospital of Inner Mongolia Medical College, The fourth Hospital of Inner Mongolia, Zhongshan People's Hospital, Guangdong, China, Fenyang Hospital of Shanxi Province, The First Hospital Of Huhhot, Taiyuan Xinghualing Maternity & Child Health Care Center, The Fifth People's Hospital of Datong, Shanxi Provincial Maternity and Children's Hospital, The Second People's Hospital of Jinzhong, The Second Hospital of Hebei Medical University, People's Hospital of Rongcheng, Hebei Zhaoxian People's Hospital, Hejian Municipal People's Hospital, Xinle Municipal Hospital of Hebei, Capital Medical University, Fengtai district Hospital of Chinese and Western medicine, Beijing, Shanghai Changzheng Hospital, Xintai People's Hospital
- Study start
- Jan 2014
- Primary completion
- Aug 2015 (actual)
- First posted
- 24 Mar 2014 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Tanreqing Injection is widely used in respiratory disease with Chinese medicine syndrome of retention of phlegm and heat in Fei. This study record clinical use of Tanreqing Injection in the real world, observe the adverse drug reactions/ adverse drug events during treatment, and figure out why Tanreqing induced severe allergic reaction happens.
Detailed description
As a compound traditional Chinese medicine, Tanreqing Injection was approved by China Food and Drug Administration(CFDA) in 2003, and widely used respiratory disease, such as biofilm related upper respiratory infections, pneumonia and bronchitis. During its 11 years marketing in China, there was hardly any serious adverse drug reactions except for a few cases reported as severe allergic reaction. In this study, clinical pharmacists in selected hospitals will not only record the clinical use and the adverse drug reactions/ adverse drug events of this injection, but also try to figure out why drug-induced severe allergic reaction happens through a nested case-control study. This real world study for Tanreqing Injection with 30400 patients will be conducted from January.2014 to June.2016.
Study design
- Observational model
- Cohort
- Target follow-up
- 7 Days
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Tanreqing | – | –Inpatient using the Tanreqing Injection |
Who may qualify
- Ages
- 24 months and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
- Study population
- Patients who use the Tanreqing Injection in selected hospitals in China (including the inpatient and the outpatient(only in some hospitals which can get the information)).
Key inclusion criteria (2 listed)
- Patients who use the Tanreqing Injection in selected hospitals in China, including inpatient and outpatient.
- Outpatients will be only in some hospitals which can get the patients' complete information.
Key exclusion criteria (1 listed)
- Patients who are less than 24 months.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Incidence of adverse drug reaction of Tanreqing Injection
Time frame: 30 months
5 secondary outcomes
Outcomes of the patients who experienced an adverse drug reaction of Tanreqing Injection
Time frame: 30 months
Administration of Tanreqing Injection in real world
Time frame: 30 months
Population characteristics of the adverse drug reaction of Tanreqing Injection
Time frame: 30 months
Off-lable use of Tanreqing Injection
Time frame: 30 months
Drug combination of Tanreqing Injection in real world
Time frame: 30 months
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 19 Feb 2016.
Related trials for Adverse Drug Reaction
Not yet recruitingPhase 2
The Impact of Using Nicorandil for the Prevention of Doxorubicin-Induced Cardiotoxicity
Doxorubicin Induced Cardiotoxicity, Doxorubicin Induced Cardiomyopathy
Not yet recruiting
Feasibility Study of Huangqi Yangyuan Formula for Capecitabine-Induced Adverse Reactions in Advanced Colorectal Cancer
Advanced Colorectal Cancer, Capecitabine-Related Adverse Reaction
RecruitingPhase 4
Propofol-Ketamine Versus Sevoflurane for Laryngeal Mask Anesthesia in Pediatric Cardiac Catheterization
Propofol, Ketamine
Active, not recruiting
Introducing Electronic Alerts to Reduce Inappropriate Digoxin Prescribing in Older Adults
Drug-Related Side Effects and Adverse Reaction, Digoxin Overdose
RecruitingObservational study
Reduction of Adverse Drug Events and Readmissions
Pharmacogenomic Testing for Medication Management
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
90 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Adverse Drug Reaction and Drug Allergy, run by Suodi ZHAI at 90 sites in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 19 Feb 2016. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 90 sites in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Incidence of adverse drug reaction of Tanreqing Injection (time frame: 30 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 19 Feb 2016.